NASDAQ:ARAY - Accuray Stock Price, Price Target & More

$5.10 0.00 (0.00 %)

(As of 04/26/2018 04:00 PM ET)

Previous Close$5.10

Today's Range$5.05 - $5.15

52-Week Range$3.60 - $6.15

Volume307,409 shs

Average Volume824,825 shs

Market Capitalization$430.73 million

P/E Ratio-14.17

Dividend YieldN/A

Beta1.73

About Accuray (NASDAQ:ARAY)

Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. The CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of precise, high dose radiation while patients breathe normally. It also offers the TomoTherapy System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. The company markets its products in the United States directly, as well as through a sales agent and group purchasing organizations; and directly and through distributors and sales agents in Europe, Japan and other countries of Asia, South America, and internationally to hospitals and stand-alone treatment facilities. Accuray Incorporated was incorporated in 1990 and is headquartered in Sunnyvale, California.

Receive ARAY News and Ratings via Email

Sign-up to receive the latest news and ratings for ARAY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments

Sub-IndustryHealth Care Equipment

SectorMedical

SymbolNASDAQ:ARAY

CUSIP00439710

Webwww.accuray.com

Phone408-716-4600

Debt

Debt-to-Equity Ratio2.66%

Current Ratio1.54%

Quick Ratio0.99%

Price-To-Earnings

Trailing P/E Ratio-14.17

Forward P/E Ratio-26.84

P/E GrowthN/A

Sales & Book Value

Annual Sales$383.41 million

Price / Sales1.13

Cash FlowN/A

Price / CashN/A

Book Value$0.56 per share

Price / Book9.11

Profitability

EPS (Most Recent Fiscal Year)($0.36)

Net Income$-29,570,000.00

Net Margins-6.09%

Return on Equity-44.66%

Return on Assets-5.20%

Miscellaneous

Employees944

Outstanding Shares85,290,000

How to Become a New Pot Stock Millionaire

Accuray (NASDAQ:ARAY) Frequently Asked Questions

What is Accuray's stock symbol?

Accuray trades on the NASDAQ under the ticker symbol "ARAY."

How were Accuray's earnings last quarter?

Accuray Incorporated (NASDAQ:ARAY) issued its earnings results on Tuesday, January, 23rd. The medical equipment provider reported ($0.06) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.11) by $0.05. The medical equipment provider earned $100.33 million during the quarter, compared to the consensus estimate of $90.31 million. Accuray had a negative return on equity of 44.66% and a negative net margin of 6.09%. The firm's revenue for the quarter was up 14.7% compared to the same quarter last year. During the same period last year, the business posted ($0.11) EPS. View Accuray's Earnings History.

When is Accuray's next earnings date?

Accuray is scheduled to release their next quarterly earnings announcement on Monday, April, 30th 2018. View Earnings Estimates for Accuray.

What price target have analysts set for ARAY?

6 equities research analysts have issued 12-month price objectives for Accuray's shares. Their predictions range from $6.00 to $10.00. On average, they anticipate Accuray's share price to reach $7.40 in the next year. View Analyst Ratings for Accuray.

Who are some of Accuray's key competitors?

Some companies that are related to Accuray include Irhythm Technologies (IRTC), Mazor Robotics (MZOR), Intersect ENT (XENT), ATRION (ATRI), Orthofix (OFIX), Glaukos (GKOS), OraSure Technologies (OSUR), Luminex (LMNX), K2M Group (KTWO), MiMedx Group (MDXG), CryoLife (CRY), Cardiovascular Systems (CSII), LeMaitre Vascular (LMAT), AngioDynamics (ANGO) and AtriCure (ATRC).

Who are Accuray's key executives?

Accuray's management team includes the folowing people:

Mr. Joshua H. Levine, Pres, Chief Exec. Officer & Director (Age 60)
Mr. Kevin Waters, Sr. VP & CFO (Age 41)
Mr. Andrew Kirkpatrick, Sr. VP of Global Operations (Age 55)
Ms. Alaleh Nouri, Sr. VP, Gen. Counsel & Corp. Sec. (Age 39)
Mr. Lionel Hadjadjeba, Sr. VP & Chief Commercial Officer (Age 59)

Has Accuray been receiving favorable news coverage?

Media stories about ARAY stock have trended positive recently, Accern Sentiment reports. Accern ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Accuray earned a coverage optimism score of 0.41 on Accern's scale. They also gave media coverage about the medical equipment provider an impact score of 45.77 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.

How do I buy shares of Accuray?

Shares of ARAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Accuray's stock price today?

One share of ARAY stock can currently be purchased for approximately $5.10.

How big of a company is Accuray?

Accuray has a market capitalization of $430.73 million and generates $383.41 million in revenue each year. The medical equipment provider earns $-29,570,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Accuray employs 944 workers across the globe.

How can I contact Accuray?

Accuray's mailing address is 1310 CHESAPEAKE TERRACE, SUNNYVALE CA, 94089. The medical equipment provider can be reached via phone at 408-716-4600 or via email at [email protected]

MarketBeat Community Rating for Accuray (ARAY)

Community Ranking:		2.8 out of 5 ( )
Outperform Votes:		230 (Vote Outperform)
Underperform Votes:		186 (Vote Underperform)
Total Votes:		416

MarketBeat's community ratings are surveys of what our community members think about Accuray and other stocks. Vote "Outperform" if you believe ARAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARAY will underperform the S&P 500 over the long term. You may vote once every thirty days.

Accuray (NASDAQ:ARAY) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

6 Wall Street analysts have issued ratings and price targets for Accuray in the last 12 months. Their average twelve-month price target is $7.40, suggesting that the stock has a possible upside of 45.10%. The high price target for ARAY is $10.00 and the low price target for ARAY is $6.00. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Buy
Consensus Rating Score:	2.33	2.33	2.43	2.50
Ratings Breakdown:	1 Sell Rating(s) 2 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 2 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 2 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 3 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$7.40	$7.40	$7.3333	$6.60
Price Target Upside:	45.10% upside	35.78% upside	34.56% upside	45.05% upside

Accuray (NASDAQ:ARAY) Consensus Price Target History

Price Target History for Accuray (NASDAQ:ARAY)

Accuray (NASDAQ:ARAY) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/10/2018	Royal Bank of Canada	Set Price Target	Hold	$6.00	High
12/13/2017	JPMorgan Chase	Downgrade	Neutral -> Underweight	$6.00	High
11/30/2017	Lake Street Capital	Initiated Coverage	Buy -> Buy	$10.00	High
10/27/2017	Cowen	Reiterated Rating	Buy	$9.00	N/A
8/24/2017	BTIG Research	Reiterated Rating	Hold		Medium
8/23/2017	Jefferies Group	Lower Price Target	Buy	$7.00 -> $6.00	Low
3/21/2017	Aegis	Reiterated Rating	Buy		Medium
8/18/2016	Morgan Stanley	Set Price Target	Hold	$8.00	N/A
5/22/2016	Brean Capital	Reiterated Rating	Buy	$12.00	N/A

(Data available from 4/26/2016 forward)

Accuray (NASDAQ:ARAY) Earnings History and Estimates Chart

Earnings by Quarter for Accuray (NASDAQ:ARAY)

Accuray (NASDAQ:ARAY) Earnings Estimates

2018 EPS Consensus Estimate: ($0.17)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.04)	($0.04)	($0.04)
Q2 2018	1	($0.10)	($0.10)	($0.10)
Q3 2018	1	($0.04)	($0.04)	($0.04)
Q4 2018	1	$0.01	$0.01	$0.01

Accuray (NASDAQ ARAY) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
4/30/2018		($0.05)					N/A
1/23/2018	Q2 18	($0.11)	($0.06)	$90.31 million	$100.33 million	View	Listen
10/24/2017	Q1 2018	($0.09)	($0.07)	$88.26 million	$91.00 million	View	N/A
8/22/2017	6/30/2017	($0.01)	($0.06)	$112.00 million	$112.09 million	View	N/A
4/27/2017	Q3 2017	$0.0120	($0.06)	$110.23 million	$97.31 million	View	N/A
1/31/2017	Q217	($0.09)	($0.11)	$93.74 million	$87.50 million	View	Listen
10/27/2016	Q117	($0.10)	($0.12)	$37.34 million	$86.50 million	View	Listen
8/17/2016	Q316	($0.07)	($0.09)	$98.97 million	$95.00 million	View	Listen
4/26/2016	Q316	($0.06)	$0.01	$102.79 million	$105.30 million	View	Listen
1/28/2016	Q216	($0.08)	($0.08)	$101.15 million	$108.90 million	View	Listen
10/29/2015	Q116	($0.14)	($0.12)	$88.60 million	$89.60 million	View	Listen
8/20/2015	Q415	($0.04)	($0.07)	$102.41 million	$101.80 million	View	Listen
4/30/2015	Q315	($0.06)	($0.04)	$102.72 million	$97.50 million	View	Listen
1/27/2015	Q215	($0.08)	($0.13)	$98.87 million	$98.20 million	View	Listen
10/29/2014	Q115	($0.13)	($0.28)	$88.90 million	$82.40 million	View	Listen
8/21/2014	Q414	($0.07)	($0.13)	$92.23 million	$102.00 million	View	Listen
4/30/2014	Q314	($0.16)	($0.06)	$82.00 million	$97.10 million	View	Listen
1/30/2014	Q214	($0.20)	($0.07)	$80.20 million	$93.60 million	View	Listen
11/7/2013	Q114	($0.20)	($0.21)	$79.67 million	$76.60 million	View	Listen
8/27/2013	Q4 2013	($0.20)	($0.20)	$82.29 million	$84.90 million	View	Listen
5/7/2013	Q3 2013	($0.22)	($0.37)	$77.97 million	$70.55 million	View	Listen
2/6/2013	Q2 2013	($0.33)	($0.30)	$74.23 million	$77.80 million	View	Listen
11/7/2012	Q113	($0.22)	($0.23)	$85.41 million	$83.00 million	View	N/A
9/6/2012	Q412	($0.12)	($0.20)	$106.92 million	$100.50 million	View	N/A
5/8/2012		($0.14)	($0.21)			View	N/A
2/8/2012	Q2 2012	($0.19)	($0.10)			View	N/A
11/8/2011		($0.29)	($0.38)			View	N/A
9/19/2011		$0.02	($0.40)			View	N/A
5/5/2011		$0.04	($0.02)			View	N/A
1/27/2011		($0.01)	$0.07			View	N/A
11/8/2010	Q1 2011	($0.07)	($0.08)			View	N/A
8/31/2010	Q4 2010	$0.05	$0.08			View	N/A
5/6/2010	Q3 2010	$0.01	$0.04			View	N/A
2/4/2010	Q2 2010	($0.01)	($0.02)			View	N/A
10/29/2009	Q1 2010	($0.03)	($0.06)			View	N/A
8/24/2009	Q4 2009	$0.03	$0.02			View	N/A
5/5/2009	Q3 2009	$0.02	$0.05			View	N/A
1/29/2009	Q2 2009	$0.02	$0.02			View	N/A
12/18/2008	Q1 2009	$0.02	($0.06)			View	N/A
4/29/2008	Q3 2008	$0.05	$0.01			View	N/A
1/30/2008	Q2 2008	$0.12	$0.04			View	N/A

(Earnings results data provided by Zacks Investment Research)

Accuray (NASDAQ:ARAY) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Accuray (NASDAQ ARAY) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.90%
Institutional Ownership Percentage: 82.11%

Insider Trading History for Accuray (NASDAQ:ARAY)

Institutional Ownership by Quarter for Accuray (NASDAQ:ARAY)

Accuray (NASDAQ ARAY) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/3/2018	Alaleh Nouri	SVP	Sell	2,585	$4.65	$12,020.25	204,483
4/3/2018	Joshua Levine	CEO	Sell	8,675	$4.65	$40,338.75	1,426,753
4/3/2018	Kevin Waters	CFO	Sell	2,997	$4.65	$13,936.05	328,260
12/1/2017	Alaleh Nouri	SVP	Sell	2,166	$4.86	$10,526.76	207,068
12/1/2017	Joshua Levine	CEO	Sell	17,093	$4.86	$83,071.98	1,435,428
12/1/2017	Kevin Waters	CFO	Sell	7,154	$5.06	$36,199.24	335,087
10/4/2017	Kelly Londy	COO	Sell	99,136	$4.24	$420,336.64
11/9/2015	Joshua Levine	CEO	Buy	50,000	$7.12	$356,000.00	1,115,830
2/2/2015	Alaleh Nouri	SVP	Sell	5,164	$7.38	$38,110.32
11/30/2014	Alaleh Nouri	SVP	Sell	268	$6.62	$1,774.16
11/30/2014	Kelly Londy	EVP	Sell	2,273	$6.62	$15,047.26
11/3/2014	Joshua Levine	CEO	Buy	100,000	$6.34	$634,000.00
5/6/2014	Joshua Levine	CEO	Buy	50,000	$8.15	$407,500.00	531,210
2/4/2014	Richard Pettingill	Director	Buy	9,795	$10.33	$101,182.35	43,940
12/4/2013	Jack Goldstein	Director	Sell	7,000	$7.70	$53,900.00	66,237
12/3/2013	Elizabeth Davila	Director	Sell	8,000	$7.74	$61,920.00	77,137
9/4/2013	Darren J Milliken	SVP	Sell	11,002	$6.53	$71,843.06
3/5/2013	Dennis L Winger	Director	Buy	20,000	$4.30	$86,000.00
2/13/2013	Joshua Levine	CEO	Buy	100,000	$4.38	$438,000.00

(Data available from 1/1/2013 forward)

Accuray (NASDAQ ARAY) News Headlines

Source:

Date	Headline
	Accuray (ARAY) Upgraded to Hold at BidaskClub www.americanbankingnews.com - April 26 at 1:31 PM
	South Florida Radiation Oncology Treats First Cancer Patients Using Its New CyberKnife® M6™ System www.prnewswire.com - April 24 at 9:02 AM
	Analysts Expect Accuray Incorporated (ARAY) Will Announce Quarterly Sales of $98.18 Million www.americanbankingnews.com - April 19 at 2:50 AM
	Accuray Incorporated (ARAY) Given Consensus Recommendation of "Hold" by Brokerages www.americanbankingnews.com - April 18 at 9:14 AM
	Accuray (ARAY) to Release Quarterly Earnings on Wednesday www.americanbankingnews.com - April 18 at 1:52 AM
	Accuray (ARAY) Rating Increased to Hold at Zacks Investment Research www.americanbankingnews.com - April 17 at 10:55 PM
	Zacks: Brokerages Expect Accuray Incorporated (ARAY) Will Announce Earnings of -$0.03 Per Share www.americanbankingnews.com - April 17 at 3:19 PM
	Accuray amène les patients au cœur des innovations dans le traitement du cancer à l'ESTRO 37 www.prnewswire.com - April 17 at 7:49 AM
	Accuray (ARAY) Rating Lowered to Strong Sell at Zacks Investment Research www.americanbankingnews.com - April 16 at 9:17 PM
	Accuray (ARAY) Cut to "Sell" at BidaskClub www.americanbankingnews.com - April 15 at 2:21 PM
	Royal Bank of Canada Reiterates "$6.00" Price Target for Accuray (ARAY) www.americanbankingnews.com - April 10 at 12:30 PM
	Accuray To Report Fiscal 2018 Third Quarter Financial Results On April 30, 2018 finance.yahoo.com - April 9 at 9:15 AM
	BidaskClub Downgrades Accuray (ARAY) to Sell www.americanbankingnews.com - April 5 at 10:26 AM
	Accuray (ARAY) Earns Buy Rating from Cowen www.americanbankingnews.com - April 4 at 5:52 PM
	Alaleh Nouri Sells 2,585 Shares of Accuray Incorporated (ARAY) Stock www.americanbankingnews.com - April 3 at 11:05 PM
	Accuray Incorporated (ARAY) CFO Sells $13,936.05 in Stock www.americanbankingnews.com - April 3 at 11:04 PM
	Joshua Levine Sells 8,675 Shares of Accuray Incorporated (ARAY) Stock www.americanbankingnews.com - April 3 at 10:44 PM
	$98.18 Million in Sales Expected for Accuray Incorporated (ARAY) This Quarter www.americanbankingnews.com - April 2 at 2:48 AM
	Accuray Incorporated (ARAY) Expected to Post Earnings of -$0.03 Per Share www.americanbankingnews.com - March 31 at 3:14 PM
	Accuray Radixact Picked by India's Apollo for Cancer Treatment finance.yahoo.com - March 29 at 4:47 PM
	Accuray Radixact Picked by India's Apollo for Cancer Treatment www.zacks.com - March 29 at 9:24 AM
	Accuray Banks on Acquisition & Partnership Amid Competition www.zacks.com - March 28 at 9:19 AM
	Apollo Hospitals in India to Acquire Two Accuray Radixact® Systems www.prnewswire.com - March 28 at 7:51 AM
	Accuray (ARAY) Stock Rating Lowered by Zacks Investment Research www.americanbankingnews.com - March 27 at 1:51 PM
	Erasmus MC Completes First Step in the Evolution of Online Adaptive Radiation Therapy with the CyberKnife® System finance.yahoo.com - March 27 at 9:26 AM
	Accuray Incorporated (ARAY) Receives Consensus Recommendation of "Hold" from Analysts www.americanbankingnews.com - March 24 at 8:10 AM
	Technical Perspectives on Medical Equipment Stocks -- Accuray, AcelRx Pharma, Aethlon Medical, and CHF Solutions www.bizjournals.com - March 20 at 9:18 AM
	Zacks: Brokerages Anticipate Accuray Incorporated (ARAY) to Announce -$0.03 EPS www.americanbankingnews.com - March 14 at 2:53 PM
	Accuray Gains on Radixact Unit, Solid Geographical Foothold - Nasdaq www.nasdaq.com - March 14 at 9:54 AM
	Accuray Gains on Radixact Unit, Solid Geographical Foothold finance.yahoo.com - March 13 at 6:38 PM
	Cogentix Medical (CGNT) Looks Good: Stock Adds 13.3% in Session finance.yahoo.com - March 13 at 9:17 AM
	Boston Scientific (BSX) vs. Accuray (ARAY) Financial Analysis www.americanbankingnews.com - March 8 at 1:52 PM
	Accuray (ARAY) Cut to "Hold" at Zacks Investment Research www.americanbankingnews.com - March 7 at 12:42 PM
	Accuray (ARAY) Upgraded to Buy by Zacks Investment Research www.americanbankingnews.com - March 6 at 5:16 PM
	Sectoral Asset Management Inc Sells 92,100 Shares of Accuray Incorporated (ARAY) www.americanbankingnews.com - March 6 at 2:10 PM
	Bogle Investment Management L P DE Buys Shares of 445,197 Accuray Incorporated (ARAY) www.americanbankingnews.com - March 5 at 5:10 AM
	Critical Comparison: Accuray (ARAY) versus IRIDEX (IRIX) www.americanbankingnews.com - March 4 at 1:32 PM
	Accuray Incorporated (ARAY) Short Interest Update www.americanbankingnews.com - March 3 at 1:52 AM
	Spark Investment Management LLC Purchases 193,600 Shares of Accuray Incorporated (ARAY) www.americanbankingnews.com - February 28 at 5:52 PM
	A Look at Accuray’s Therapy Systems finance.yahoo.com - February 28 at 5:20 PM
	How Accuray Has Performed Financially finance.yahoo.com - February 28 at 5:20 PM
	How Much Is Accuray’s Target Market Expected to Grow? finance.yahoo.com - February 28 at 5:20 PM
	Zacks Investment Research Downgrades Accuray (ARAY) to Hold www.americanbankingnews.com - February 28 at 4:03 PM
	Accuray (ARAY) Rating Increased to Buy at Zacks Investment Research www.americanbankingnews.com - February 27 at 2:02 PM
	Accuray Incorporated (ARAY) Shares Bought by Royce & Associates LP www.americanbankingnews.com - February 27 at 12:11 PM
	Accuray Incorporated (ARAY) Given Average Recommendation of "Hold" by Brokerages www.americanbankingnews.com - February 27 at 7:24 AM
	Analysts Anticipate Accuray Incorporated (ARAY) Will Announce Quarterly Sales of $98.18 Million www.americanbankingnews.com - February 27 at 4:56 AM
	Adirondack Research & Management Inc. Invests $1.08 Million in Accuray Incorporated (ARAY) Stock www.americanbankingnews.com - February 26 at 5:16 AM
	Analysts Expect Accuray Incorporated (ARAY) to Announce -$0.03 EPS www.americanbankingnews.com - February 25 at 1:16 PM
	Accuray (ARAY) Presents At RBC Capital Markets Global Healthcare Conference - Slideshow seekingalpha.com - February 23 at 5:15 PM

Accuray (NASDAQ:ARAY) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Accuray (NASDAQ:ARAY) Income Statement, Balance Sheet and Cash Flow Statement

Accuray (NASDAQ ARAY) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff